486 related articles for article (PubMed ID: 16569595)
1. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
2. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
3. Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.
Belle S; Han F; Condomines M; Christensen O; Witzens-Harig M; Kasper B; Kleist C; Terness P; Moos M; Cremer F; Hose D; Ho AD; Goldschmidt H; Klein B; Hundemer M
Eur J Haematol; 2008 Jul; 81(1):26-35. PubMed ID: 18363871
[TBL] [Abstract][Full Text] [Related]
4. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.
Jalili A; Ozaki S; Hara T; Shibata H; Hashimoto T; Abe M; Nishioka Y; Matsumoto T
Blood; 2005 Nov; 106(10):3538-45. PubMed ID: 16037388
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
6. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
[TBL] [Abstract][Full Text] [Related]
7. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
[TBL] [Abstract][Full Text] [Related]
9. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
[TBL] [Abstract][Full Text] [Related]
10. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
[TBL] [Abstract][Full Text] [Related]
11. Identification of CD8
Ma N; Liu H; Zhang Y; Liu W; Liang Z; Wang Q; Sun Y; Wang L; Li Y; Ren H; Dong Y
Front Immunol; 2022; 13():927804. PubMed ID: 35967402
[TBL] [Abstract][Full Text] [Related]
12. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma.
Kang YJ; Zeng W; Song W; Reinhold B; Choi J; Brusic V; Yamashita T; Munshi A; Li C; Minvielle S; Anderson KC; Munshi N; Reinherz EL; Sasada T
Br J Haematol; 2013 Nov; 163(3):343-51. PubMed ID: 24032635
[TBL] [Abstract][Full Text] [Related]
13. Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays.
Wu X; Xu X; Gu R; Wang Z; Chen H; Xu K; Zhang M; Hutton J; Yang T
Autoimmunity; 2012 Mar; 45(2):176-85. PubMed ID: 22260783
[TBL] [Abstract][Full Text] [Related]
14. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
Rew SB; Peggs K; Sanjuan I; Pizzey AR; Koishihara Y; Kawai S; Kosaka M; Ozaki S; Chain B; Yong KL
Clin Cancer Res; 2005 May; 11(9):3377-84. PubMed ID: 15867238
[TBL] [Abstract][Full Text] [Related]
15. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
Bae J; Tai YT; Anderson KC; Munshi NC
Br J Haematol; 2011 Nov; 155(3):349-61. PubMed ID: 21902685
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
17.
Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
Front Immunol; 2019; 10():1792. PubMed ID: 31428094
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
[TBL] [Abstract][Full Text] [Related]
19. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.
Liu F; Zhang H; Shen D; Wang S; Ye Y; Chen H; Pang X; Song Q; He P
J Gastroenterol; 2014 Mar; 49(3):419-26. PubMed ID: 23604623
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.
Imahashi N; Nishida T; Ito Y; Kawada J; Nakazawa Y; Toji S; Suzuki S; Terakura S; Kato T; Murata M; Naoe T
Mol Immunol; 2013 Dec; 56(4):399-405. PubMed ID: 23911395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]